Clinical trials: Sunitinib, completed
Renal Cell Carcinoma 4
Cardiovascular Effects of Sunitinib Therapy (CREST)
Tyrosine kinase inhibitors such as sunitinib are used in the treatment of renal cell carcinoma and have significant off-target effects with cardiac toxicity and resultant ventricular cardiac dysfunction being a major concern.
- Trial name
- NCT01370109
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Gastrointestinal Stromal Tumor(GIST)
A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib
the primary objective of this study is to assess the efficacy (progression-free survival,PFS) of DCC-2618 (ripretinib, ZL-2307) and sunitinib in patients with advanced gastrointestinal stromal tumors after treatment with…
- Trial name
- NCT04633122
- Testing
- Ripretinib, Sunitinib
- Where
- 18 sites in China
- Volunteers
- 108 people
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Kidney Neoplasms
The Pharmacokinetic Variability of Sunitinib in Patients With Metastatic Renal Cancer
The primary objective of this study is to determine the percentage of patients with a plasma concentration of sunitinib remaining at equilibrium ([Suni]REq) greater than 100 ng / ml (effective concentration according to the…
- Trial name
- GenCInibs-Suni (NCT02404584)
- Testing
- Blood drawn for genotyping, Blood drawn for pharmacokinetic measures
- Where
- 3 sites in France
- Volunteers
- 43 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia
This phase IB trial studies the feasibility of using a functional laboratory based study to determine how well the test can be used to select personalized kinase inhibitor therapy in combination with standard chemotherapy in…
- Trial name
- NCT02779283
- Testing
- Cyclophosphamide, Cytarabine, Dasatinib
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- OHSU Knight Cancer Institute
Colorectal Neoplasms
Assessment Of Safety And Efficacy Of SU11248 In Patients With Metastatic Colorectal Cancer Who Have Failed Selected Previous Treatments.
Assessment of safety and efficacy of SU11248 in patients with metastatic colorectal cancer who have failed selected previous treatments.
- Trial name
- NCT00077987
- Testing
- SU011248
- Volunteers
- 84 people
- Sponsor
- Pfizer
Gastrointestinal Stromal Tumors
Sorafenib for Imatinib/Sunitinib-failed GIST
With discovery of KIT (CD117) mutations and the advent of KIT tyrosine kinase inhibitor imatinib, there has been substantial improvement in overall survival in patients with advanced and/or metastatic gastrointestinal tumors…
- Trial name
- NCT01091207
- Testing
- Sorafenib
- Where
- South Korea
- Volunteers
- 39 people
- Sponsor
- Samsung Medical Center
Cancer
Predictive Value of Drug Elimination Gene Polymorphisms on Clearance and Dose Adjustment of Sunitinib in Cancer Patients
Sunitinib is an anticancer drug, but like most drugs, the effect varies from person to person. This is partly due to a variation in how well each person eradicates the drug from the body.
- Trial name
- CLEARSUN (NCT01098903)
- Where
- 3 sites in Australia, Netherlands
- Volunteers
- 52 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Inflammatory Breast Cancer, Male Breast Cancer
Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer
This phase II trial studies how well giving sunitinib malate together with paclitaxel, doxorubicin hydrochloride, and cyclophosphamide before surgery works in treating patients with stage IIB-IIIC breast cancer.
- Conditions
- Inflammatory Breast Cancer, Male Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
- Trial name
- NCT00513695
- Testing
- sunitinib malate, paclitaxel, doxorubicin hydrochloride
- Where
- 7 sites in United States
- Volunteers
- 68 people
- Sponsor
- University of Washington
Metastatic Cancer
N-of-1 Trial: Actionable Target Identification in Metastatic Cancer for Palliative Systemic Therapy
The metastatic lesions may be very different from the primary tumor because of intrinsic tumor heterogenity, clonal selection through metastatic process and following previous cytotoxic treatments.
- Trial name
- MetAction (NCT02142036)
- Testing
- EMA-approved ATI based targeted therapy
- Where
- 2 sites in Norway
- Volunteers
- 50 people
- Sponsor
- Oslo University Hospital
Metastatic Clear Cell Renal Cell Carcinoma
Validation of a Predictive Nomogram of Response or Resistance to Targeted Therapies in Metastatic Clear Cell Renal Cell Carcinoma
The purpose of this study is to validate of a predictive nomogram of response or resistance to targeted therapies in metastatic clear cell renal cell carcinoma
- Trial name
- RTKI (NCT02848768)
- Testing
- Sunitinib
- Where
- France
- Volunteers
- 45 people
- Sponsor
- Rennes University Hospital
Non GIST Sarcomas
Study of Continuous Dosing of Sunitinib in Non GIST Sarcomas With Concomitant Radiotherapy
The purpose of this study is to determine the safety of continuous dosing of sunitinib in association with radiotherapy in patients with non GIST (gastro intestinal stromal tumor) sarcomas who cannot be treated by surgery.
- Trial name
- NCT01308034
- Testing
- sunitinib
- Where
- 6 sites in France
- Volunteers
- 25 people
- Sponsor
- Centre Leon Berard
Advanced Solid Tumors
To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib.
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of AMG 386 when used in combination with AMG 706, bevacizumab, sorafenib, or sunitinib and that at least one dose level from each combination…
- Trial name
- NCT00861419
- Testing
- Sorafenib, AMG 706, AMG 386
- Volunteers
- 88 people
- Sponsor
- Amgen
Breast Neoplasms
Open Label Study Of SU011248 In Combination With Trastuzumab For Patients With Metastatic Breast Cancer
The current study is to evaluate: Overall response rate for the combination of trastuzumab and SU011248 in metastatic or locally recurrent breast cancer; evaluate safety and tolerability of the combination; measure duration of…
- Trial name
- NCT00243503
- Testing
- SU011248/Trastuzumab
- Where
- 27 sites in United States, Belgium and 3 more
- Volunteers
- 60 people
- Sponsor
- Pfizer
Renal Cell Cancer Metastatic, Hypertension
Sunitinib Treatment on Tissue Sodium Accumulation (TSS2)
Here, it is investigated how sunitinib, a tyrosine kinase-inhibitor targeting vascular endothelial growth factor receptors, might influence sodium homeostasis in the skin and if this is related to a well-described treatment…
- Conditions
- Renal Cell Cancer Metastatic, Hypertension, Sodium Imbalance
- Trial name
- NCT04368546
- Testing
- Sunitinib
- Where
- Germany
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Charite University, Berlin, Germany
Gastrointestinal Stromal Tumors
Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib.
With the development of KIT mutation and KIT tyrosine kinase inhibitor imatinib (GlivecTM, Novartis), survival of patients with advanced and/or metastatic gastrointestinal stromal tumor (GIST) has significantly improved.
- Trial name
- NCT03944304
- Testing
- Paclitaxel
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Asan Medical Center
Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
The purpose of this study is to compare the objective response rate, progression free survival and the overall survival of Nivolumab combined with Ipilimumab to Sunitinib monotherapy in patients with previously untreated Renal…
- Trial name
- NCT02231749
- Testing
- Nivolumab, Ipilimumab, Sunitinib
- Where
- 189 sites in United States, Argentina and 26 more
- Volunteers
- 1,096 people
- Sponsor
- Bristol-Myers Squibb
Carcinoma, Renal Cell
Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib.
Research Questions: To understand the clinical outcomes of patients treated with sunitinib in first line and axitinib in second line in a real world setting as therapies for metastatic and/or advanced renal cell carcinoma (mRCC).
- Trial name
- NCT04033991
- Testing
- Sunitinib, Axitinib
- Where
- United Kingdom
- Volunteers
- 684 people
- Sponsor
- Pfizer
Renal Cell Cancer, Renal Cell Carcinoma
A Study to Describe the Kidney Cancer Patient Population Treatment, and Results in the Hospital District of Southwest Finland.
The purpose of the study is to find out how patients with advanced kidney cancer have been treated in the hospital district of Southwest Finland over time.
- Conditions
- Renal Cell Cancer, Renal Cell Carcinoma, Cancer of Kidney, Cancer of the Kidney
- Trial name
- NCT05363072
- Where
- Finland
- Volunteers
- 1,112 people
- Sponsor
- Pfizer
Kidney Neoplasms, Carcinoma, Renal Cell
Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI
To learn whether Flourine-18 Fluoro-deoxi-glucose positron emission tomography / computed tomography (F-18 FDG PET/CT) and dynamic contrast enhanced magnetic resonance imaging (DCE MRI) are better predictors of response to…
- Conditions
- Kidney Neoplasms, Carcinoma, Renal Cell, Kidney (Renal Cell) Cancer
- Trial name
- NCT00537056
- Testing
- FDG PET CT, DCE MRI, F-18 Fluoro-deoxi-glucose
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Stanford University
Unresectable and Advanced Cholangiocarcinoma
A Study of Sunitinib in Patients With Advanced Cholangiocarcinoma
For patients with non-resectable cholangiocarcinoma, gemcitabine with cisplatin is considered as the reference treatment in first line chemotherapy.
- Trial name
- SUN-CK (NCT01718327)
- Testing
- Sunitinib
- Where
- 6 sites in France
- Volunteers
- 53 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group